Auricular Vagus Nerve Acupressure for Patients with Emotional Distress under the COVID-19 Pandemic: A Smartphone-based, Randomized,Controlled Trial (Preprint)
P. Rong, Lei Wang, Lingling Yu, Junying Wang, Yanzhen Ma, Liting Wang, Suxia Li, Chun-lin Tang, Liming Lu, Liang Li, Jiazi Dong, J. Fang, Liwei Hou, Zongshi Qin, Xiao-lan Su, Yufeng Zhao, Zhangjin Zhang
{"title":"Auricular Vagus Nerve Acupressure for Patients with Emotional Distress under the COVID-19 Pandemic: A Smartphone-based, Randomized,Controlled Trial (Preprint)","authors":"P. Rong, Lei Wang, Lingling Yu, Junying Wang, Yanzhen Ma, Liting Wang, Suxia Li, Chun-lin Tang, Liming Lu, Liang Li, Jiazi Dong, J. Fang, Liwei Hou, Zongshi Qin, Xiao-lan Su, Yufeng Zhao, Zhangjin Zhang","doi":"10.2196/preprints.25001","DOIUrl":null,"url":null,"abstract":"\n BACKGROUND\n The global spread of the 2019 coronavirus diseases (COVID-19) has caused emotional distress. However, whether auricular vagus nerve acupressure (AVNA) is effective in improving emotional distress under the COVID-19 has not been well-documented.\n \n \n OBJECTIVE\n To confirm whether AVNA is effective in improving emotional distress under the COVID-19 pandemic.\n \n \n METHODS\n A smartphone-based online, randomized, controlled trial was designed in four study sites, including Wuhan, Beijing, Shenyang, and Guangzhou of China, from 26 February 2020 to 28 April 2020. Participants were randomly assigned to three times of AVNA (n = 191) or usual care (UC, n = 215) for 14 days. The primary outcome was the response rate, which was the proportion of participants whose Hospital Anxiety and Depression Scale (HADS) score reduced from baseline by ≥ 50%. The assessment was conducted at baseline, 3 days, and 14 days.\n \n \n RESULTS\n The AVNA group had a markedly higher response rate than the UC group at 3 days (35.6% vs. 24.9%, P = 0.02) and at 14 days (70.7% vs. 60.6%, P = 0.02). The AVNA group showed significantly greater reduction in score of HADS at the two measurement points and BAI at 3 days (P ≤ 0.03), with average respective effect size of 0.217 and 0.195. Participants with AVNA spent less time falling asleep and rated their sleep quality being remarkably higher than those with UC at endpoint.\n \n \n CONCLUSIONS\n AVNA can be recommended for patients with emotional distress under the current COVID-19 pandemic and other emergent events.\n \n \n CLINICALTRIAL\n www.chictr.org.cn Identifier: ChiCTR2000030078.\n","PeriodicalId":23141,"journal":{"name":"TMR Modern Herbal Medicine","volume":"27 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TMR Modern Herbal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/preprints.25001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
BACKGROUND
The global spread of the 2019 coronavirus diseases (COVID-19) has caused emotional distress. However, whether auricular vagus nerve acupressure (AVNA) is effective in improving emotional distress under the COVID-19 has not been well-documented.
OBJECTIVE
To confirm whether AVNA is effective in improving emotional distress under the COVID-19 pandemic.
METHODS
A smartphone-based online, randomized, controlled trial was designed in four study sites, including Wuhan, Beijing, Shenyang, and Guangzhou of China, from 26 February 2020 to 28 April 2020. Participants were randomly assigned to three times of AVNA (n = 191) or usual care (UC, n = 215) for 14 days. The primary outcome was the response rate, which was the proportion of participants whose Hospital Anxiety and Depression Scale (HADS) score reduced from baseline by ≥ 50%. The assessment was conducted at baseline, 3 days, and 14 days.
RESULTS
The AVNA group had a markedly higher response rate than the UC group at 3 days (35.6% vs. 24.9%, P = 0.02) and at 14 days (70.7% vs. 60.6%, P = 0.02). The AVNA group showed significantly greater reduction in score of HADS at the two measurement points and BAI at 3 days (P ≤ 0.03), with average respective effect size of 0.217 and 0.195. Participants with AVNA spent less time falling asleep and rated their sleep quality being remarkably higher than those with UC at endpoint.
CONCLUSIONS
AVNA can be recommended for patients with emotional distress under the current COVID-19 pandemic and other emergent events.
CLINICALTRIAL
www.chictr.org.cn Identifier: ChiCTR2000030078.
背景2019冠状病毒病(COVID-19)的全球传播引发了情绪困扰。然而,耳穴迷走神经指压(AVNA)是否有效改善COVID-19下的情绪困扰尚未得到充分的证明。目的探讨AVNA是否能有效改善新冠肺炎大流行背景下的情绪困扰。方法于2020年2月26日至2020年4月28日在中国武汉、北京、沈阳和广州4个研究地点设计一项基于智能手机的在线、随机、对照试验。参与者被随机分配到3次AVNA (n = 191)或常规护理(n = 215),持续14天。主要终点是应答率,即医院焦虑和抑郁量表(HADS)评分较基线降低≥50%的参与者比例。评估分别在基线、第3天和第14天进行。结果AVNA组治疗3 d (35.6% vs. 24.9%, P = 0.02)和14 d (70.7% vs. 60.6%, P = 0.02)的有效率明显高于UC组。AVNA组在两个测点的HADS评分和3 d的BAI评分均有显著性降低(P≤0.03),平均效应量分别为0.217和0.195。AVNA患者入睡时间更短,睡眠质量评分明显高于UC患者。结论在当前COVID-19大流行及其他突发事件的情况下,可以推荐AVNA用于情绪困扰患者。临床试验www.chictr.org.cn标识符:ChiCTR2000030078。